← Back to Clinical Trials
Recruiting Phase 1 NCT03860233

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

Trial Parameters

Condition Sleep Apnea
Sponsor Vivek Jain
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2019-03-04
Completion 2025-12-01
Interventions
OxytocinPlacebo

Brief Summary

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.

Eligibility Criteria

Inclusion Criteria: * Men or women 18 years of age or older. Exclusion Criteria: * subjects not willing to or otherwise unable to use CPAP for treatment of OSA. * Presence of other sleep disorders * Pregnant or breastfeeding women * Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study * Prisoners or subjects who are involuntarily incarcerated * Subjects who are compulsorily detain or treatment of either a psychiatric or physical (i.e. infectious disease) illness * Patients unable to give consent because of a language barrier, or other reason.

Related Trials